Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q2

4483.TEDINET S100S9E5
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥13.7bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥7.0bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥27.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥12.1bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.3bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥3.6bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥1.1bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥2.2bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.1bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥3.6bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.1bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥5.9bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥2.2bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.1bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥2.7bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥621m2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥678m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥2.7bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥623m2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥677m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥100.0bnat 2023-09-30Cons.Assets IFRS
Total assets¥98.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥112.1bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥31.3bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥34.0bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥68.7bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥64.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥61.6bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥68.6bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥64.5bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥61.6bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥21.5bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥22.8bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥41.5bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥2.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥4.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥3.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥21.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥341m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥28.3bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥48.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥42.22023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥9.832023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥71.172022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥25.292022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥11.762022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥40.532023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥9.462023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥67.692022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥23.862022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥11.142022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio68.6%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio65.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio55.0%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 71
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥89m
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-09-30−¥13m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥89m
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-09-30−¥13m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥338m
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-09-30−¥187m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-04-01 → 2023-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-07-01 → 2023-09-30¥292m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-07-01 → 2023-09-30¥292m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥50m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-04-01 → 2023-09-30¥133m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-07-01 → 2023-09-30¥45m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2023-04-01 → 2023-09-30¥9.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2023-07-01 → 2023-09-30¥5.3bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-04-01 → 2023-09-30¥9.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-07-01 → 2023-09-30¥5.3bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥38m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥13m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-04-01 → 2023-09-30¥2.5bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-07-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2023-04-01 → 2023-09-30¥2.7bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2023-07-01 → 2023-09-30¥1.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2023-04-01 → 2023-09-30¥2.7bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2023-07-01 → 2023-09-30¥1.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2023-04-01 → 2023-09-30¥1.0bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2023-07-01 → 2023-09-30¥566m
—segment totalrevenue2023-04-01 → 2023-09-30¥13.8bn
—segment totalrevenue2023-07-01 → 2023-09-30¥7.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥13.7bn
—segment totalrevenue external2023-07-01 → 2023-09-30¥7.0bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥89m
—segment totalrevenue intersegment2023-07-01 → 2023-09-30¥13m
—segment totalsegment profit2023-04-01 → 2023-09-30¥3.6bn
—segment totalsegment profit2023-07-01 → 2023-09-30¥1.8bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥189m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥99m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-07-01 → 2022-09-30¥933m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-07-01 → 2022-09-30¥890m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥84m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-09-30¥192m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-07-01 → 2022-09-30¥144m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-07-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-07-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥24m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-07-01 → 2022-09-30¥903m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-09-30¥924m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-07-01 → 2022-09-30¥485m
—segment totalrevenue2022-04-01 → 2022-09-30¥12.2bn
—segment totalrevenue2022-07-01 → 2022-09-30¥6.4bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥12.1bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥6.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥126m
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥67m
—segment totalsegment profit2022-04-01 → 2022-09-30¥3.1bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 887
ItemContextValueUnit
Liabilities IFRSPrior1YearInstant34042000000JPY
Liabilities IFRSCurrentQuarterInstant31288000000JPY
Share capital IFRSPrior1YearInstant23994000000JPY
Share capital IFRSCurrentQuarterInstant25094000000JPY
Capital surplus IFRSPrior1YearInstant27211000000JPY
Capital surplus IFRSCurrentQuarterInstant28298000000JPY
Treasury shares IFRSPrior1YearInstant-2000000JPY
Treasury shares IFRSCurrentQuarterInstant-2000000JPY
Other components of equity IFRSPrior1YearInstant28000000JPY
Other components of equity IFRSCurrentQuarterInstant25000000JPY
Retained earnings IFRSPrior1YearInstant13308000000JPY
Retained earnings IFRSCurrentQuarterInstant15221000000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant64539000000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant68635000000JPY
Non controlling interests IFRSPrior1YearInstant-14000000JPY
Non controlling interests IFRSCurrentQuarterInstant76000000JPY
Equity IFRSPrior1YearInstant64524000000JPY
Equity IFRSCurrentQuarterInstant68712000000JPY
Liabilities and equity IFRSPrior1YearInstant98567000000JPY
Liabilities and equity IFRSCurrentQuarterInstant100000000000JPY
Revenue IFRSPrior1YTDDuration12060000000JPY
Revenue IFRSCurrentYTDDuration13746000000JPY
Cost of sales IFRSPrior1YTDDuration5342000000JPY
Cost of sales IFRSCurrentYTDDuration6171000000JPY
Gross profit IFRSPrior1YTDDuration6717000000JPY
Gross profit IFRSCurrentYTDDuration7575000000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration4697000000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration5346000000JPY
Other income IFRSPrior1YTDDuration203000000JPY
Other income IFRSCurrentYTDDuration1479000000JPY
Other expenses IFRSPrior1YTDDuration14000000JPY
Other expenses IFRSCurrentYTDDuration106000000JPY
Operating profit loss IFRSPrior1YTDDuration2207000000JPY
Operating profit loss IFRSCurrentYTDDuration3602000000JPY
Finance income IFRSPrior1YTDDuration68000000JPY
Finance income IFRSCurrentYTDDuration29000000JPY
Finance costs IFRSPrior1YTDDuration42000000JPY
Finance costs IFRSCurrentYTDDuration17000000JPY
Profit loss before tax IFRSPrior1YTDDuration2234000000JPY
Profit loss before tax IFRSCurrentYTDDuration3615000000JPY
Income tax expense IFRSPrior1YTDDuration797000000JPY
Income tax expense IFRSCurrentYTDDuration951000000JPY
Profit loss IFRSPrior1YTDDuration1436000000JPY
Profit loss IFRSCurrentYTDDuration2663000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration1444000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration2662000000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration-7000000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration0JPY
Profit loss IFRSPrior1YTDDuration1436000000JPY
Profit loss IFRSCurrentYTDDuration2663000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass